Pfizer Inc. on Tuesday said that its preliminary laboratory tests of an antiviral Covid-19 pill, Paxlovid, still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients while retaining effectiveness against the new omicron variant.
The positive results from Pfizer come as the U.S. Food and Drug Administration is reviewing whether to clear use of Paxlovid in high-risk adults.
Earlier today, new study showed that two shots of Pfizer vaccine may give 70% protection against being hospitalized with Omicron Covid-19 variant, according to South Africa’s largest medical-insurance provider, Discovery Ltd.
